Efficacy of irbesartan in arterial hypertension and metabolic syndrome
Abstract
About the Authors
O. D. OstroumovaRussian Federation
A. A. Zykova
Russian Federation
T. A. Polosova
Russian Federation
O. V. Bondarets
Russian Federation
References
1. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Кардиоваскулярная терапия и профилактика. 2009; 6 (Прил. 2): 1–29.
2. Lakka H.M, Laaksonen D.E, Lakka T.A et al. The metabolic syndrome and total and cardiovascular disease mortality in middle - aged men. JAMA 2002; 288: 2709–16.
3. Howard G, O'Leary D.H, Zaccaro D et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93 (10): 1809–17.
4. Mule G, Nardi E, Cottone S et al. Infl uence of metabolic syndrome on hypertension - related target organ damage. J Intern Med 2005; 257: 503–13.
5. Schilacci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978–82.
6. Cuspidi C, Meani S, Fusi V et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875–82.
7. Kavamoto R, Tomita H, Oka Y et al. Metabolic syndrome amplifi es the LDL - cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232–8.
8. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
9. Клиническая фармакология. Под ред. В.Г.Кукеса. 4 - е изд. М.: ГЭОТАР - Медиа, 2008; с. 392–5.
10. Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
11. Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
12. Pfeffer M.A, Swedberg K, Granger C.B et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.
13. Neutel J.M, Saunders E, Bakris G.L et al. The efficacy and safety of lowand high - dose fixed combinations of irbe irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7: 578–86.
14. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007; с. 56–73.
15. Sowers J.R, Neutel J.M, Saunders E et al. Behalf of the INCLUSIVE Investigators. Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. J Clin Hypertens 2006; 8: 470–80.
16. Parhofer K.G, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO - IT prospective observational study. Cardiovasc Diabetol 2007; 6: 36.
17. Kintscher U, Bramlage P, Paar W.D et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.
Review
For citations:
Ostroumova O.D., Zykova A.A., Polosova T.A., Bondarets O.V. Efficacy of irbesartan in arterial hypertension and metabolic syndrome. Systemic Hypertension. 2013;10(2):53-56.
Email this article 